University Hospital Krakow
Welcome,         Profile    Billing    Logout  
 14 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dudek, Dariusz
RedStroke, NCT04108884: - Reducing Europe's Stroke Incidence

Completed
N/A
1019
Europe
App measurement, 14 day Holter ECG
University Hospital, Basel, Switzerland, European Union, Preventicus GmbH
Atrial Fibrillation
01/24
01/24
NCT04883008: NAVIGATE GRX Study

Terminated
N/A
50
Europe
CorPath GRX with technIQ automated movements enabled (technIQ ON), CorPath GRX with technIQ automated movements disabled (technIQ OFF).
Corindus Inc.
Coronary Artery Disease
02/22
02/22
FULL REVASC, NCT02862119: Ffr-gUidance for compLete Non-cuLprit REVASCularization

Completed
N/A
1542
Europe
FFR Treatment Arm, Conservative Treatment Arm
Felix Bohm, Uppsala University, The Swedish Research Council, Swedish Heart Lung Foundation, Abbott, Boston Scientific Corporation
Coronary Artery Disease, ST-elevation Myocardial Infarction
07/23
07/23
TESLA, NCT05841745: Multicenter Registry on Robotically Assisted PCI -

Recruiting
N/A
700
Europe, Japan
Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System
Clinical Research Center, Intercard Sp. z o.o., Corindus, Inc. dba Siemens Healthineers Endovascular Robotics, KCRI Sp. z o.o.
Coronary Artery Disease
12/23
07/24
Relan, Anurag
AKI, NCT04912141: Prevention of Acute Kidney Injury in Patients With NSTEMI

Terminated
2
29
Europe
conestat alfa or placebo, Ruconest
Pharming Technologies B.V.
Non-ST Elevation Myocardial Infarction (NSTEMI)
04/23
04/23
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Recruiting
N/A
300
Europe, RoW
rhC1INH or pdC1INH, Ruconest
Pharming Technologies B.V.
Hereditary Angioedema
01/25
01/25
Jesenak, Milos
NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Recruiting
2/3
75
Europe, US, RoW
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Takeda, Takeda Development Center Americas, Inc.
Primary Immunodeficiency Diseases (PID)
02/26
09/26
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Recruiting
N/A
300
Europe, RoW
rhC1INH or pdC1INH, Ruconest
Pharming Technologies B.V.
Hereditary Angioedema
01/25
01/25

Download Options